CANDEL THERAPEUTICS, INC. Labor and Related Expense
CANDEL THERAPEUTICS, INC. (CADL) reported Labor and Related Expense of $2.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LaborAndRelatedExpense · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. labor and related expense for the quarter ending 2026-06-30 was $2.69M, a 38.25% increase year-over-year.
- CANDEL THERAPEUTICS, INC. labor and related expense for the quarter ending 2026-03-31 was $2.37M, a 37.88% increase year-over-year.
- CANDEL THERAPEUTICS, INC. labor and related expense for the quarter ending 2025-12-31 was $2.02M, a 22.47% increase year-over-year.
- CANDEL THERAPEUTICS, INC. labor and related expense for the quarter ending 2025-09-30 was $1.95M, a 15.97% increase year-over-year.
- CANDEL THERAPEUTICS, INC. labor and related expense for fiscal 2025 was $7.62M, a 11.61% increase from fiscal 2024.
- CANDEL THERAPEUTICS, INC. labor and related expense for fiscal 2024 was $6.83M, a 9.80% decline from fiscal 2023.
- CANDEL THERAPEUTICS, INC. labor and related expense for fiscal 2023 was $7.57M.
| Period end | Labor and Related Expense 3 month | Labor and Related Expense 6 month | Labor and Related Expense 9 month | Labor and Related Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.69M 10-Q · filed 2026-08-13 | $5.05M 10-Q · filed 2026-08-13 | $7.07M derived: sum of 3 quarters · filed 2026-08-13 | $9.02M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $2.37M 10-Q · filed 2026-05-14 | $4.38M derived: sum of 2 quarters · filed 2026-05-14 | $6.33M derived: sum of 3 quarters · filed 2026-05-14 | $8.27M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.96M derived: sum of 2 quarters · filed 2026-03-12 | $5.91M derived: sum of 3 quarters · filed 2026-08-13 | $7.62M 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.95M 10-Q · filed 2025-11-13 | $3.89M derived: sum of 2 quarters · filed 2026-08-13 | $5.61M 10-Q · filed 2025-11-13 | $7.25M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.95M 10-Q · filed 2026-08-13 | $3.66M 10-Q · filed 2026-08-13 | $5.31M derived: sum of 3 quarters · filed 2026-08-13 | $6.99M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.72M 10-Q · filed 2026-05-14 | $3.36M derived: sum of 2 quarters · filed 2026-05-14 | $5.04M derived: sum of 3 quarters · filed 2026-05-14 | $6.91M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.33M derived: sum of 2 quarters · filed 2026-03-12 | $5.19M derived: sum of 3 quarters · filed 2026-03-12 | $6.83M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.68M 10-Q · filed 2025-11-13 | $3.54M derived: sum of 2 quarters · filed 2025-11-13 | $5.18M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $1.87M 10-Q · filed 2025-08-14 | $3.51M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $1.64M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $7.57M 10-K · filed 2025-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |